Physician profile
Kenneth E Wasserman
NPI 1346254703
$944.40
in general payments reported to CMS, 2019-2025
11 companies · $494 in 2025
The $494 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $159 · 2024: $292 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $222.72 | 2024-2025 | |
| Incyte Corporation | $155.68 | 2025 | Opzelura |
| Almirall LLC | $145.34 | 2024 | Klisyri |
| Sun Pharmaceutical Industries INC. | $140.33 | 2025 | |
| Dermavant Sciences, INC. | $106.57 | 2023 | Vtama |
| Leo Pharma INC. | $73.37 | 2025 | Adbry |
| Pfizer INC. | $36.89 | 2023 | |
| Radius Health, INC. | $16.19 | 2024 | Tymlos |
| Mannkind Corporation | $15.96 | 2024 | |
| Lilly USA, LLC | $15.83 | 2023 | Taltz |
| Janssen Biotech, INC. | $15.52 | 2024 | Simponi Aria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.